drugset / Trial / NCT00711646

A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.

NCT00711646

Phase 3 Completed 189 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of Sativex® in subjects diagnosed with MS and spasticity.

Timeline

Start
2002-06
Primary completion
2004-03
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Nabiximols Other / unclassified Other

Indications